Michelle J Lee1,2, Jean L Koff3, Jeffrey M Switchenko4, C Ileen Jhaney3, R Andrew Harkins1, Sharvil P Patel3, Sandeep S Dave5, Christopher R Flowers3,6. 1. Emory University School of Medicine, Atlanta, Georgia, USA. 2. Department of Medicine, Morehouse School of Medicine, Atlanta, Georgia, USA. 3. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. 4. Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA. 5. Center for Genomic and Computational Biology, Duke Cancer Institute, Duke University, Durham, North Carolina, USA. 6. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
BACKGROUND: Significant racial differences have been observed in the incidence and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) in the United States, but to the authors' knowledge it remains unclear whether genomic differences contribute to these disparities. METHODS: To understand the influences of genetic ancestry on tumor genomic alterations, the authors estimated the genetic ancestry of 1001 previously described patients with DLBCL using unsupervised model-based Admixture global ancestry analysis applied to exome sequencing data and examined the mutational profile of 150 DLBCL driver genes in tumors obtained from this cohort. RESULTS: Global ancestry prediction identified 619 patients with >90% European ancestry, 81 patients with >90% African ancestry, and 50 patients with >90% Asian ancestry. Compared with patients with DLBCL with European ancestry, patients with African ancestry were aged >10 years younger at the time of diagnosis and were more likely to present with B symptoms, elevated serum lactate dehydrogenase, extranodal disease, and advanced stage disease. Patients with African ancestry demonstrated worse overall survival compared with patients with European ancestry (median, 4.9 years vs 8.8 years; P = .04). Recurrent mutations of MLL2 (KMT2D), HIST1H1E, MYD88, BCL2, and PIM1 were found across all ancestry groups, suggesting shared mechanisms underlying tumor biology. The authors also identified 6 DLBCL driver genes that were more commonly mutated in patients with African ancestry compared with patients with European ancestry: ATM (21.0% vs 7.75%; P < .001), MGA (19.7% vs 5.33%; P < .001), SETD2 (17.3% vs 5.17%; P < .001), TET2 (12.3% vs 5.82%; P = .029), MLL3 (KMT2C) (11.1% vs 4.36%; P = .013), and DNMT3A (11.1% vs 4.52%; P = .016). CONCLUSIONS: Distinct prevalence and patterns of mutation highlight an important difference in the mutational landscapes of DLBCL arising in different ancestry groups. To the authors' knowledge, the results of the current study provide the first-ever characterization of genetic alterations among patients with African descent who are diagnosed with DLBCL.
BACKGROUND: Significant racial differences have been observed in the incidence and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) in the United States, but to the authors' knowledge it remains unclear whether genomic differences contribute to these disparities. METHODS: To understand the influences of genetic ancestry on tumor genomic alterations, the authors estimated the genetic ancestry of 1001 previously described patients with DLBCL using unsupervised model-based Admixture global ancestry analysis applied to exome sequencing data and examined the mutational profile of 150 DLBCL driver genes in tumors obtained from this cohort. RESULTS: Global ancestry prediction identified 619 patients with >90% European ancestry, 81 patients with >90% African ancestry, and 50 patients with >90% Asian ancestry. Compared with patients with DLBCL with European ancestry, patients with African ancestry were aged >10 years younger at the time of diagnosis and were more likely to present with B symptoms, elevated serum lactate dehydrogenase, extranodal disease, and advanced stage disease. Patients with African ancestry demonstrated worse overall survival compared with patients with European ancestry (median, 4.9 years vs 8.8 years; P = .04). Recurrent mutations of MLL2 (KMT2D), HIST1H1E, MYD88, BCL2, and PIM1 were found across all ancestry groups, suggesting shared mechanisms underlying tumor biology. The authors also identified 6 DLBCL driver genes that were more commonly mutated in patients with African ancestry compared with patients with European ancestry: ATM (21.0% vs 7.75%; P < .001), MGA (19.7% vs 5.33%; P < .001), SETD2 (17.3% vs 5.17%; P < .001), TET2 (12.3% vs 5.82%; P = .029), MLL3 (KMT2C) (11.1% vs 4.36%; P = .013), and DNMT3A (11.1% vs 4.52%; P = .016). CONCLUSIONS: Distinct prevalence and patterns of mutation highlight an important difference in the mutational landscapes of DLBCL arising in different ancestry groups. To the authors' knowledge, the results of the current study provide the first-ever characterization of genetic alterations among patients with African descent who are diagnosed with DLBCL.
Authors: Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet Journal: Blood Date: 2005-09-08 Impact factor: 22.113
Authors: Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald Journal: Blood Date: 2005-07-26 Impact factor: 22.113
Authors: Christopher R Flowers; Pareen J Shenoy; Uma Borate; Kevin Bumpers; Tanyanika Douglas-Holland; Nassoma King; Otis W Brawley; Joseph Lipscomb; Mary Jo Lechowicz; Rajni Sinha; Rajinder S Grover; Leon Bernal-Mizrachi; Jeanne Kowalski; Will Donnellan; Angelina The; Vishnu Reddy; David L Jaye; James Foran Journal: Leuk Lymphoma Date: 2013-02
Authors: Daniel C Koboldt; Krishna L Kanchi; Bin Gui; David E Larson; Robert S Fulton; William B Isaacs; Aldi Kraja; Ingrid B Borecki; Li Jia; Richard K Wilson; Elaine R Mardis; Adam S Kibel Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-02 Impact factor: 4.254
Authors: Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz Journal: JCO Precis Oncol Date: 2017-05-16
Authors: M J Maurer; T M Habermann; Q Shi; N Schmitz; D Cunningham; M Pfreundschuh; J F Seymour; U Jaeger; C Haioun; H Tilly; H Ghesquieres; F Merli; M Ziepert; R Herbrecht; J Flament; T Fu; C R Flowers; B Coiffier Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Faith O Abodunrin; Oluwasegun A Akinyemi; Ademola S Ojo; Kindha Elleissy Nasef; Thomas Haupt; Ayobami Oduwole; Oni Olanrewaju; Bolarinwa Akinwumi; Mary Fakorede; Oluwaseun Ogunbona Journal: Cureus Date: 2022-06-12
Authors: Wilfred Leung; Matt Teater; Ceyda Durmaz; Cem Meydan; Alexandra G Chivu; Amy Chadburn; Edward J Rice; Ashlesha Muley; Jeannie M Camarillo; Jaison Arivalagan; Ziyi Li; Christopher R Flowers; Neil L Kelleher; Charles G Danko; Marcin Imielinski; Sandeep S Dave; Scott A Armstrong; Christopher E Mason; Ari M Melnick Journal: Cancer Discov Date: 2022-07-06 Impact factor: 38.272